Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Expected to Rise, Lake Street Capital Analyst Says

Bolt Biotherapeutics (NASDAQ:BOLT) had its target price upped by equities research analysts at Lake Street Capital to $75.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Stifel Nicolaus dropped their price objective on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a “hold” rating for the company in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $47.50.

Bolt Biotherapeutics Price Performance

NASDAQ BOLT traded down $0.1450 on Friday, hitting $4.9250. The stock had a trading volume of 28,434 shares, compared to its average volume of 15,618. The firm has a 50-day moving average of $5.85 and a 200-day moving average of $7.14. The company has a market capitalization of $9.44 million, a price-to-earnings ratio of -0.18 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.13 and a current ratio of 3.13. Bolt Biotherapeutics has a 52-week low of $4.76 and a 52-week high of $14.36.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($4.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.40) by $1.94. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.82 million. Equities analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at approximately $25,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics during the 4th quarter valued at approximately $26,000. Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $27,000. Finally, Citadel Advisors LLC purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $42,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.